T1	Participants 92 121	patients with Crohn's disease
T2	Participants 385 438	patients from 17 centres in Australia and New Zealand
T3	Participants 598 715	Patients at high risk of recurrence also received a thiopurine, or adalimumab if they were intolerant to thiopurines.
T4	Participants 1709 1721	122 patients
